ライフサイエンスコーパス: anorexia

1 d intake when infected (i.e. illness-induced anorexia).

2 directly engage CGRP(PBN) neurons to promote anorexia.

3 pnea, abdominal swelling, bipedal edema, and anorexia.

4 local Fos induction that is associated with anorexia.

5 lation and may be involved in other forms of anorexia.

6 a, hyperbilirubinemia, hypophosphatemia, and anorexia.

7 tion/withdrawal behavior, hypervigilance and anorexia.

8 CeA, precipitated anxiety-like behavior and anorexia.

9 ly obese adult Lep(ob/ob) mice caused severe anorexia.

10 , thrombocytopenia, fever, rash, chills, and anorexia.

11 C)Rs) significantly attenuated D-Fen-induced anorexia.

12 heir inhibition after symptom onset reverses anorexia.

13 aracterized QT adaptation during exercise in anorexia.

14 nditure, but did not affect estrogen-induced anorexia.

15 eported adverse events in the QnC group were anorexia (12 [12%] of 98 patients), abnormal behaviour (

16 Anorexia (13 [6%] of 233 patients) was the most frequent

17 ), dysgeusia (29%), muscle cramps (29%), and anorexia (14%).

18 17 [6%]), fatigue (27 [9%] and 21 [7%]), and anorexia (19 [6%] and 11 [4%]).

19 gue (42 [42%]), thrombocytopenia (35 [35%]), anorexia (26 [26%]), neutropenia (24 [24%]), constipatio

20 reported in the re-treatment ACT group were anorexia (31 [13%] of 240 patients), asthenia (20 [8%]),

21 y (27 [23%] vs 60 [51%]), but more grade 1-4 anorexia (33 [28%] vs 10 [8%]), constipation (29 [25%] v

22 vs 26 [7%]), vomiting (47 [14%] vs 15 [4%]), anorexia (37 [11%] vs 13 [4%]), photosensitivity (42 [12

23 ablation or silencing of AgRP neurons causes anorexia [4, 5], whereas selective stimulation in fed mi

24 ne), stomatitis (56% v 7%), rash (44% v 7%), anorexia (43% v 18%), and diarrhea (39% v 11%).

25 mmon major nonhematologic toxic effects were anorexia (5%) and fatigue (3%).

26 ents (AEs) were nausea (75%), fatigue (70%), anorexia (64%), vomiting (43%), weight loss (32%), and d

27 events included fatigue (70%), nausea (70%), anorexia (66%), and vomiting (49%), which were generally

28 icities during cycle one were fatigue (94%), anorexia (67%), alterations in liver enzymes (64%), and

29 ed a mean of 8.2 AEs; the most frequent were anorexia (79.2%), nausea (75.5%), headache (60.4%), amne

30 anced physical activity in an activity-based anorexia (ABA) mouse model, hypothalamic expression of b

31 The activity-based anorexia (ABA) phenomenon models aspects of AN in rodent

32 eural mechanisms mediating cisplatin-induced anorexia, advancing opportunities to develop better-tole

33 ivity, an estimate of fibers connections, in anorexia after recovery in tracts that connect taste-rew

34 nse physical effort, and was associated with anorexia and asthenia.

35 ceptor blockade attenuates cisplatin-induced anorexia and body weight loss in addition to pica, demon

36 eptor or IL-6 biological activity attenuated anorexia and body weight loss induced by central exendin

37 and melanocortin receptors 3/4 reversed the anorexia and body weight loss induced by TLR2 activation

38 N-->CeA neurons attenuated cisplatin-induced anorexia and body weight loss significantly.

39 -->lPBN neurons attenuated cisplatin-induced anorexia and body weight loss significantly.

40 ral amygdala) PACAP dose-dependently induced anorexia and body weight loss without affecting locomoto

41 ns and are resistant to chemotherapy-induced anorexia and body weight loss.

42 eceptor signaling mediates cisplatin-induced anorexia and body weight loss.

43 Older women appear less likely to exhibit anorexia and bulimia nervosa and more likely to exhibit

44 s with advanced cancer frequently experience anorexia and cachexia, which are associated with reduced

45 a treatment option for patients with cancer anorexia and cachexia.

46 otherapies and adjuvant therapies to prevent anorexia and concurrent nutritional deficiencies during

47 as statistically significant class effect on anorexia and diarrhea AEs.

48 Anorexia and early satiety are common, but putative caus

49 ased energy intake and expenditure, although anorexia and higher weight loss have been reported in el

50 Chronic heart failure is accompanied by anorexia and increased release of B-type natriuretic pep

51 Melancholic patients experience anorexia and insomnia, whereas atypical patients experie

52 ) neurons before tumor implantation prevents anorexia and loss of lean mass, and their inhibition aft

53 between anorexia nervosa and schizophrenia, anorexia and obesity, and educational attainment and sev

54 elated protein (AgRP) in adult mice leads to anorexia and starvation within 7 d that is caused by hyp

55 e of the activation of stress systems can be anorexia and subsequent weight loss, and both the activa

56 reas through which the PACAP system promotes anorexia and that PACAP preferentially lessens the maint

57 neuroanatomical circuit driving pathological anorexia and weight loss that accompanies chemotherapy t

58 y used to treat cancers despite accompanying anorexia and weight loss that may limit treatment adhere

59 ion in posterior BNST subregions can produce anorexia and weight loss, and corroborate growing data i

60 ting GFRAL as the receptor for GDF15-induced anorexia and weight loss, we identify a mechanistic basi

61 n neurons are required for cisplatin-induced anorexia and weight loss, we inhibited these neurons che

62 -forebrain projections for cisplatin-induced anorexia and weight loss.

63 fective treatments for, chemotherapy-induced anorexia and weight loss.

64 ull expression of cisplatin-induced malaise, anorexia, and body weight loss.

65 ms, along with a decrease in pain, insomnia, anorexia, and constipation in both arms.

66 ns (fatigue, nausea/vomiting, pain, dyspnea, anorexia, and constipation).

67 during hospitalization were fever, weakness, anorexia, and diarrhea, although 21% of patients were in

68 rowing, developed severe ataxia, tremor, and anorexia, and died by postnatal day 15.

69 Mucositis, anorexia, and dizziness were more prevalent in the rotat

70 -HT2C, receptor is critical for weight loss, anorexia, and fat mass reduction induced by central GLP-

71 grative medicine, can attenuate weight loss, anorexia, and fatigue in patients with cancer.

72 events (grade 1 or 2) were nausea, vomiting, anorexia, and fatigue, which were well managed with supp

73 3.2% v. 33.3%, respectively), rash, fatigue, anorexia, and hypokalemia, but not more late toxicity.

74 Patients with CKD suffer from food aversion, anorexia, and malnutrition.

75 ents included rash, hyperglycemia, diarrhea, anorexia, and mood alteration (37% each); nausea (31%);

76 iated with sickness responses such as fever, anorexia, and stress hormone release.

77 They typically have a history of lethargy, anorexia, and weight loss in the months preceding the il

78 episode (MDE), such as low mood, anhedonia, anorexia, and weight loss.

79 Secondary outcomes included anorexia, anxiety, depression, and symptom distress scor

80 Nausea, emesis, and anorexia are common features of these disorders.

81 Temporary anorexia associated with an infection is often beneficia

82 ogical conditions such as in the fatigue and anorexia associated with autoimmune diseases, with major

83 less likely than nonpregnant women to report anorexia, asthenia, diarrhea, fever, myalgias/arthralgia

84 in two of three symptoms (pain, fatigue, or anorexia) at week 8 compared with baseline measurements.

85 "sickness syndrome," characterized by fever, anorexia, behavioral withdrawal, acute-phase protein res

86 was not an indirect consequence of fever or anorexia but that it constituted an independent inflamma

87 l pathogen, Salmonella Typhimurium, inhibits anorexia by manipulating the gut-brain axis.

88 We discovered that SirT1 depletion causes anorexia by stimulating production of inflammatory facto

89 Anorexia-cachexia syndrome (ACS) is a major determinant

90 Cancer anorexia-cachexia syndrome is associated with increased

91 cal response profile in patients with cancer anorexia-cachexia syndrome.

92 markers, and safety in patients with cancer anorexia-cachexia.

93 lity of life by the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire.

94 evels and/or signaling, such as diabetes and anorexia, can degrade DAT function and that insulin-inde

95 Typhimurium effector, SlrP, prevented anorexia caused by IL-1beta-mediated signaling to the hy

96 for work-up because of generalized fatigue, anorexia, chronic diarrhea, and weight loss.

97 , Wang et al. identify that sickness-induced anorexia differentially shapes the metabolic requirement

98 tically wasteful and maladaptive response to anorexia during the development of cachexia.

99 severity for nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, fatigue, pain, paresthesi

100 ated with being a MVD case included hiccups, anorexia, fatigue, vomiting, sore throat, and difficulty

101 haracterized by abdominal pain, weight loss, anorexia, generalized weakness, and fatigue.

102 nalysis found that only the restricting type anorexia group showed a positive correlation between the

103 eloped sickness behavior symptoms, including anorexia, hypoactivity, and hyperthermia.

104 thalamus (DMH) of rats with exercise-induced anorexia, implying that central TTR may also play a func

105 k cycle escalates into bulimia for many, and anorexia in a few.

106 nutrient self-medication and illness-induced anorexia in caterpillars of the African armyworm (Spodop

107 s clarify the complex and contextual role of anorexia in host-pathogen interactions and suggest that

108 wn of regulation associated with obesity and anorexia in humans?

109 Here, we investigated the role of anorexia in models of bacterial and viral infections.

110 neurobiological mechanism for GLP-1-induced anorexia in rats, involving direct effects of a GLP-1 ag

111 ive DRD2 agonist cabergoline, which produced anorexia in wild-type and ghrelin(-)/(-) mice; intriguin

112 st defenses, pathogen-mediated inhibition of anorexia increased host survival.

113 Anorexia is a common manifestation of chronic diseases,

114 Cancer cachexia/anorexia is a complex syndrome that involves profound me

115 Sickness-induced anorexia is a conserved behavior induced during infectio

116 Although induction of anorexia is a well-documented effect of PACAP, the centr

117 This anorexia leads to inadequate protein and energy intake,

118 stereotypic behavioral responses, including anorexia, lethargy, and social withdrawal.

119 eported abdominal pain, facial and jaw pain, anorexia, lethargy, weakness, and night sweats; imaging

120 adache, dizziness, myalgias, abdominal pain, anorexia, leukopenia, lymphopenia, thrombocytopenia, or

121 re we investigate the contribution to cancer anorexia made by calcitonin gene-related peptide (CGRP)

122 ferase (n = 2), diarrhea (n = 1), and nausea/anorexia (n = 1).

123 y patients and physicians of six toxicities (anorexia, nausea, vomiting, constipation, diarrhea, and

124 anges in steroid metabolism in subjects with anorexia nervosa (AN) after weight gain have not been el

125 Patients with anorexia nervosa (AN) and obesity (OB) were investigated

126 Both anorexia nervosa (AN) and obesity are complicated by aff

127 Anorexia nervosa (AN) and related eating disorders are c

128 sensitivity to reward, yet individuals with anorexia nervosa (AN) are not motivated to eat when star

129 ntless pursuit of thinness, individuals with anorexia nervosa (AN) engage in maladaptive behaviors (r

130 Individuals with anorexia nervosa (AN) engage in relentless restrictive e

131 al body weight is disrupted in patients with anorexia nervosa (AN) for prolonged periods of time.

132 Anorexia nervosa (AN) is a complex and heritable eating

133 Anorexia nervosa (AN) is a complex neuropsychiatric diso

134 Anorexia nervosa (AN) is a devastating psychiatric illne

135 Anorexia nervosa (AN) is a serious disorder with high ra

136 Anorexia nervosa (AN) is a serious eating disorder chara

137 Anorexia nervosa (AN) is a serious eating disorder chara

138 Anorexia nervosa (AN) is a severe psychiatric disorder a

139 Anorexia nervosa (AN) is an eating disorder characterize

140 Anorexia Nervosa (AN) is characterized by Diagnostic and

141 Anorexia nervosa (AN) is characterized by extremely low

142 nts were included in the dataset as follows: Anorexia Nervosa (AN) n = 171; Bulimia Nervosa (BN) n =

143 Is starvation in anorexia nervosa (AN) or overeating in bulimia nervosa (

144 Individuals with anorexia nervosa (AN) override the drive to eat, forgoin

145 orts have been carried out on iron status in anorexia nervosa (AN) patients.

146 Individuals with anorexia nervosa (AN) restrict eating and become emaciat

147 ed a genome-wide association study (GWAS) of anorexia nervosa (AN) using a stringently defined phenot

148 isms was suggested in the pathophysiology of anorexia nervosa (AN), but the role of the endogenous me

149 ve implications for eating disorders such as anorexia nervosa (AN), in which there is a high prevalen

150 distribution has previously been studied in anorexia nervosa (AN), its influence in women with AN on

151 In anorexia nervosa (AN), taste and smell are believed to b

152 onsidered one of the core characteristics of anorexia nervosa (AN), the exact nature of this complex

153 the complex eating-related behaviors seen in anorexia nervosa (AN).

154 that lead to inpatient medical treatment for anorexia nervosa (AN).

155 The study included 30 women with anorexia nervosa (mean age +/- standard deviation, 26 ye

156 omparison women (N=14), women recovered from anorexia nervosa (N=14) had significantly diminished and

157 lumes in women with current restricting-type anorexia nervosa (N=19), women recovered from restrictin

158 METHOD: Female adolescents with anorexia nervosa (N=21; mean age, 16.4 years [SD=1.9]) u

159 N=19), women recovered from restricting-type anorexia nervosa (N=24), women with bulimia nervosa (N=1

160 were aged 20-60 years and had a diagnosis of anorexia nervosa (restricting or binge-purging subtype)

161 Research in Anorexia Nervosa (RIAN) is a 2-group (FBT and SyFT) rand

162 Similar results were found for anorexia nervosa (suicide attempts: crude, 4.42 [4.12-4.

163 Anorexia nervosa affects 1-4% of women in United States

164 d circuit white matter fiber organization in anorexia nervosa after recovery could indicate a biologi

165 Anorexia nervosa also has large and significant genetic

166 The lifetime prevalence of DSM-5 anorexia nervosa among women might be up to 4%, and of b

167 ility, and genetic correlations (rg) between anorexia nervosa and 159 other phenotypes.

168 ratio was 4.37 (95% CI=2.4-7.3) for lifetime anorexia nervosa and 2.33 (95% CI=0.3-8.4) for bulimia n

169 Sixty-one adolescent female patients with anorexia nervosa and 45 age- and sex-matched healthy vol

170 e genetic correlations were observed between anorexia nervosa and body mass index, insulin, glucose,

171 unity level, 5-year recovery rates for DSM-5 anorexia nervosa and bulimia nervosa are 69 and 55%, res

172 Both anorexia nervosa and bulimia nervosa are associated with

173 Anorexia nervosa and bulimia nervosa are common and seve

174 riatum volumes were reduced in the recovered anorexia nervosa and bulimia nervosa groups and predicte

175 Course and outcome studies of both anorexia nervosa and bulimia nervosa show that no signif

176 Participants who had recovered from anorexia nervosa and bulimia nervosa were studied to avo

177 agnosis EDNOS, by lowering the threshold for anorexia nervosa and bulimia nervosa, and adding BED as

178 w is reflected by the diagnostic criteria of anorexia nervosa and bulimia nervosa, which emphasize in

179 Similar patterns were found for anorexia nervosa and bulimia nervosa.

180 ldhood'; clarifications and modifications to anorexia nervosa and bulimia nervosa; and the inclusion

181 conducted a genome-wide association study of anorexia nervosa and calculated genetic correlations wit

182 covered group (lower in women recovered from anorexia nervosa and higher in women recovered from buli

183 literature on the development and course of anorexia nervosa and interpreted critical features in li

184 he most established treatment for youth with anorexia nervosa and may be efficacious for youth with b

185 nalysis of the lumbar spine in patients with anorexia nervosa and normal-weight control subjects and

186 Women with anorexia nervosa and normal-weight control subjects were

187 tly are no significantly associated SNPs for anorexia nervosa and only three for educational attainme

188 uitry may contribute to restricted eating in anorexia nervosa and overeating in bulimia nervosa.

189 disorders: stabilization of the incidence of anorexia nervosa and possibly lower incidence rates of b

190 current first-line treatment for adolescent anorexia nervosa and promising for adolescent bulimia ne

191 umes were increased on the right side in the anorexia nervosa and recovered anorexia nervosa groups a

192 results include genetic correlations between anorexia nervosa and schizophrenia, anorexia and obesity

193 e genetic correlations were observed between anorexia nervosa and schizophrenia, neuroticism, educati

194 processes are engaged in the development of anorexia nervosa and that stimulus-response learning (th

195 on exists against schizophrenia, autism, and anorexia nervosa and that these variants may be maintain

196 on of the dieting behavior characteristic of anorexia nervosa as a well-entrenched habit provides a b

197 t restricted eating and weight loss occur in anorexia nervosa because of a failure to accurately reco

198 rmulation in which the marked persistence of anorexia nervosa can be usefully understood as a well-in

199 in 12 case-control cohorts comprising 3,495 anorexia nervosa cases and 10,982 controls, the authors

200 sted how brain reward learning in adolescent anorexia nervosa changes with weight restoration.

201 Patients with anorexia nervosa exhibit abnormal myocardial repolarizat

202 .6 (95% CI=3.2-12.1) for those with lifetime anorexia nervosa for >15 to 30 years (10/67 died).

203 (95% CI=0.9-8.3) for patients with lifetime anorexia nervosa for 0 to 15 years (4/119 died), and 6.6

204 lled female patients (aged 11-18 years) with anorexia nervosa from six centres in Germany.

205 Compared with the control group, the anorexia nervosa group exhibited greater brain response

206 t side in the anorexia nervosa and recovered anorexia nervosa groups and on the left side in the buli

207 Results Women with anorexia nervosa had higher skewness and kurtosis, lower

208 Conclusion Patients with anorexia nervosa had increased skewness and kurtosis and

209 Although anorexia nervosa has a high mortality rate, our understa

210 y, several large population-based studies of anorexia nervosa have been conducted in twins; it is pos

211 trongest evidence base for effectiveness for anorexia nervosa in adolescents.

212 nervosa subtype predicted fatal outcome for anorexia nervosa in males.

213 at birth had an independent association with anorexia nervosa in males.

214 ler discusses two trials of individuals with anorexia nervosa in which deep brain stimulation of diff

215 Anorexia nervosa is a complex heritable phenotype for wh

216 Anorexia nervosa is a life-threatening illness.

217 Anorexia nervosa is a psychiatric disorder of unknown et

218 Anorexia nervosa is a severe psychiatric disorder associ

219 Anorexia nervosa is a well characterized disorder with r

220 Anorexia nervosa is an important cause of physical and p

221 A core feature of anorexia nervosa is an over-estimation of body size.

222 Anorexia nervosa is prevalent in adolescents and young a

223 , 246 treatment-seeking female patients with anorexia nervosa or bulimia nervosa were interviewed eve

224 In humans with anorexia nervosa or kwashiorkor, ghrelin and growth horm

225 premature death among patients with lifetime anorexia nervosa peaked within the first 10 years of fol

226 The pathophysiology of anorexia nervosa remains obscure, but structural brain a

227 care in adolescent patients with non-chronic anorexia nervosa seems no less effective than IP for wei

228 and lower BMI at admission, and restrictive anorexia nervosa subtype predicted fatal outcome for ano

229 Brain circuits believed to drive anorexia nervosa symptoms can be accessed with surgical

230 ions may represent a phenotype of adolescent anorexia nervosa that does not respond well to treatment

231 contribute information about bone health in anorexia nervosa that is independent of that provided wi

232 This model helps explain the resistance of anorexia nervosa to interventions that have established

233 Adults with anorexia nervosa too have a realistic chance of achievin

234 The h(2)SNP of anorexia nervosa was 0.20 (SE=0.02), suggesting that a s

235 Anorexia nervosa was independently predicted by multiple

236 16 patients with treatment-refractory anorexia nervosa were enrolled between September, 2011,

237 tem responsiveness is elevated in adolescent anorexia nervosa when underweight and after weight resto

238 80 females (0.70%) and 453 males (0.04%) had anorexia nervosa, and 3349 females (0.30%), and 61 males

239 aptured by 3 variables (any eating disorder, anorexia nervosa, and bulimia nervosa) identified by any

240 hyperactivity disorder, alcohol dependence, anorexia nervosa, autism spectrum disorder, bipolar diso

241 purging behaviors (i.e., bulimia nervosa or anorexia nervosa, binge eating/purging type);14 with ano

242 Lifetime prevalence estimates of anorexia nervosa, bulimia nervosa, and binge-eating diso

243 uals born in 1975-1998 and followed them for anorexia nervosa, bulimia nervosa, and eating disorder n

244 moderately-to-severely ill adolescents with anorexia nervosa, but it is costly, and the risks of rel

245 n patients with chronic treatment-refractory anorexia nervosa, DBS is well tolerated and is associate

246 isorder, depression, suicide, schizophrenia, anorexia nervosa, migraine, dementia, and PD.

247 ixteen deaths (6.5%) were recorded (lifetime anorexia nervosa, N=14; bulimia nervosa with no history

248 sa, N=14; bulimia nervosa with no history of anorexia nervosa, N=2).

249 For adults with anorexia nervosa, no one specialist treatment has been s

250 enetic correlation between the Eyes Test and anorexia nervosa, openness (NEO-Five Factor Inventory),

251 t, particularly for adolescent patients with anorexia nervosa, point to the benefits of specialised f

252 nervosa, binge eating/purging type);14 with anorexia nervosa, restricting type; and 13 healthy compa

253 learning-based interventions for addiction, anorexia nervosa, schizophrenia, and depression.

254 aking to eat is crucial for survival, but in anorexia nervosa, the brain persistently supports reduce

255 closer to understanding the neurobiology of anorexia nervosa, which still remains a mystery and pose

256 The authors found that individuals with anorexia nervosa, who make maladaptive food choices to t

257 hanges in cerebral glucose metabolism in key anorexia nervosa-related structures at both 6 months and

258 I), mood, anxiety, affective regulation, and anorexia nervosa-specific behaviours at 12 months after

259 ggesting a combination of re-nourishment and anorexia nervosa-specific psychotherapy is most effectiv

260 dynamics as a risk factor for arrhythmias in anorexia nervosa.

261 ifetime weight and duration of amenorrhea in anorexia nervosa.

262 rtium Stage 1 and the Genetic Consortium for Anorexia Nervosa.

263 iety, depression, and the psychopathology of anorexia nervosa.

264 of obesity, dieting-induced weight gain, and anorexia nervosa.

265 proach in patients with, or recovering from, anorexia nervosa.

266 it was their first admission to hospital for anorexia nervosa.

267 -8.4) for bulimia nervosa with no history of anorexia nervosa.

268 functioning raise the risk for mortality in anorexia nervosa.

269 developmental delay, autism, psychosis, and anorexia nervosa.

270 degenerative diseases, obesity, bulimia, and anorexia nervosa.

271 or the treatment of eating disorders such as anorexia nervosa.

272 Dose-limiting toxicity (grade 3 anorexia) occurred in one of 18 evaluable patients at th

273 abant precipitated anxiety-like behavior and anorexia of the regular chow diet in rats withdrawn from

274 tial therapeutic target for the treatment of anorexia or other appetite disorders.

275 gement should include the following domains: anorexia or reduced food intake, catabolic drive, muscle

276 ocial phobia, obsessive-compulsive disorder, anorexia, or substance abuse), along with their mates.

277 s was associated with malaise (P = .007) and anorexia (P = .02), with previous giardiasis (P = .03),

278 ter infection, 6.7 days), fever, depression, anorexia, petechial rash, and lymphopenia.

279 eptor in PBN neurons could contribute to the anorexia phenotype.

280 ease, including a stilted gait, weight loss, anorexia, polydipsia, patterned motor behaviors, head an

281 SlrP-mediated inhibition of anorexia prevented invasion and systemic infection by wi

282 and pharmacological mechanisms mediating the anorexia produced by PACAP in the central nucleus of the

283 Women recovered from restricting-type anorexia (Recovered AN, n = 24, age = 30.3 +/- 8.1 years

284 en 3D scans of 15 women who have symptoms of anorexia (referred to henceforth as anorexia spectrum di

285 ized by cough, asthenia, sensory neuropathy, anorexia, serum sickness, and hypertensive encephalopath

286 kness syndrome occurs, which includes fever, anorexia, sleepiness, hyperalgesia and elevated corticos

287 ptoms of anorexia (referred to henceforth as anorexia spectrum disorders, ANSD) and 15 healthy contro

288 tive to both comparison and restricting type anorexia subjects in the hypothalamus and right dorsolat

289 e side effects such as nausea, vomiting, and anorexia that compromise quality of life and limit treat

290 most adverse effects, ranging from 0.10 for anorexia to 0.54 for vomiting (Cohen kappa statistic).

291 Intra-CeA PACAP-induced anorexia was blocked by coinfusion of either the melanoc

292 R1a antagonist (JMV2959) cabergoline-induced anorexia was blocked.

293 We found that anorexia was protective while nutritional supplementatio

294 Anorexia was significantly more important among colorect

295 ate quality of life (e.g., nausea, vomiting, anorexia, weight loss).

296 n of high-dose drug, which elicits lethargy, anorexia, weight loss, and peritoneal fibrosis, all of w

297 CES include constitutional symptoms (fever, anorexia, weight loss, fatigue and myalgias), signs of s

298 Vomiting, nausea, asthenia/fatigue, and anorexia were common but not severe.

299 gene slc24a4 or Nckx4), display a remarkable anorexia with severe hypophagia and weight loss.

300 ry of left inguinocrural and lumbar pain and anorexia with weight loss.